DoW Melanoma Research Program Survivorship Research Award

The Fiscal Year 2026 Melanoma Research Program Survivorship Research Award, solicitation number HT942526MRPSRA, is a funding opportunity issued by the Defense Health Agency to support innovative research aimed at improving the health and well-being of melanoma survivors, their families, and care partners. The program focuses on melanoma-specific survivorship, specifically targeting quality of life, overall health, and function. Research focusing exclusively on animal models or survival rates without considering quality of life is not responsive. Clinical trials are permitted, provided they include a strategy for the inclusion of women and minorities and register results on ClinicalTrials.gov. A mandatory requirement for all applications is the inclusion of at least one melanoma consumer collaborator, such as a survivor or a community-supporting organization, to provide lived experience expertise. The award provides a maximum of 1.02 million dollars per project over a period of performance not to exceed three years, with a total program funding goal of approximately 2.04 million dollars for two awards. Applications must be submitted via eBRAP and Grants.gov, requiring active registration in SAM.gov. The evaluation process consists of a two-tier review: a peer review focusing on research strategy and feasibility, followed by a programmatic review to determine relevance to military health and program priorities. Key deliverables include annual and final technical progress reports following RPPR standards and an award expiration transition plan. All research involving human subjects must be approved by the DHA R&D Office of Research and Regulatory Compliance.